News - Biogen Idec, Novartis

Filter

Current filters:

Biogen IdecNovartis

Popular Filters

Mixed US views on Gilenya, Aubagio and Tecfidera as breakthrough MS drugs

03-09-2013

More than half of surveyed neurologists consider US biotech firm Biogen Idec's (Nasdaq: BIIB) Tecfidera…

AubagioBiogen IdecGilenyaMarkets & MarketingNeurologicalNorth AmericaNovartisPharmaceuticalPricingSanofiTecfidera

Multiple sclerosis market could reach $18.3 billion in 2018

19-08-2013

The multiple sclerosis (MS) market is expected to peak at $18.3 billion in 2018, according to healthcare…

AubagioBiogen IdecFinancialGilenyaGlobalNovartisPharmaceuticalSanofiTecfidera

News briefs from Sanofi, Biogen/SOBI and Novartis

01-11-2012

French drug major Sanofi (Euronext: SAN) and subsidiary Genzyme have reported results from pivotal studies…

AgrippalBiogen IdecBiotechnologyFluadLemtradaNeurologicalNovartisPharmaceuticalRegulationResearchSanofiSwedish Orphan BiovitrumVaccines

US multiple sclerosis market growth remains centered on Tysabri and Gilenya ahead of Aubagio's launch

28-09-2012

The average satisfaction rating for Biogen Idec (Nasdaq: BIIB) and Elan's (NYSE: ELN) Tysabri (natalizumab).…

AubagioBiogen IdecBiotechnologyElanGilenyaMarkets & MarketingNeurologicalNorth AmericaNovartisPharmaceuticalSanofiTysabri

US neurologists' adoption of STRATIFY JCV has shifted Tysabri earlier in the treatment of some MS patients

15-08-2012

In the USA, 77% of surveyed neurologists have experience with the STRATIFY JCV assay - commercially available…

AvonexBiogen IdecElanGilenyaMarkets & MarketingNeurologicalNorth AmericaNovartisPharmaceuticalTysabri

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top